Form 8-K - Current report:
SEC Accession No. 0001193125-23-164027
Filing Date
2023-06-09
Accepted
2023-06-09 08:14:00
Documents
12
Period of Report
2023-06-08
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d501159d8k.htm   iXBRL 8-K 28668
  Complete submission text file 0001193125-23-164027.txt   153937

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA amlx-20230608.xsd EX-101.SCH 2846
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE amlx-20230608_lab.xml EX-101.LAB 18736
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amlx-20230608_pre.xml EX-101.PRE 11704
6 EXTRACTED XBRL INSTANCE DOCUMENT d501159d8k_htm.xml XML 3463
Mailing Address 43 THORNDIKE STREET CAMBRIDGE MA 02141
Business Address 43 THORNDIKE STREET CAMBRIDGE MA 02141 617-683-0917
Amylyx Pharmaceuticals, Inc. (Filer) CIK: 0001658551 (see all company filings)

EIN.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41199 | Film No.: 231003923
SIC: 2834 Pharmaceutical Preparations